Trump just signed an EO to fast-track psychedelics. ATAI ($1.4B) and GHRS ($1.04B) are Phase 3-ready with FDA Breakthrough designations.

The Setup Trump signed an executive order today directing the FDA to accelerate review of psychedelic drugs. RFK Jr., FDA Commissioner Makary, Joe Rogan, and Marcus Luttrell were all in the Oval Office for the signing. The FDA will issue national priority vouchers for three psychedelics next week — the first time in history the FDA has offered fast-tracking to any psychedelic drug. This isn’t a symbolic gesture. The FDA commissioner said these vouchers will allow certain drugs to be approved quickly “if they are in line with our national priorities.” The regulatory environment for psychedelic drug development just fundamentally changed. Two clinical-stage biotechs are positioned to benefit more than any others: ATAI (AtaiBeckley, $3.97, $1.4B market cap) and GHRS (GH Research, $16.77, $1.04B market cap). Both are developing mebufotenin (5-MeO-DMT) formulations for treatment-resistant depression. Both have FDA Breakthrough Therapy Designation. Both are initiating Phase 3 programs in 2026. Here’s the DD. ATAI — AtaiBeckley ($3.97) Formed from the merger of atai Life Sciences and Beckley Psytech in late 2025. Lead asset is BPL-003, an intranasal mebufotenin for treatment-resistant depression (TRD). The data: • Phase 2b: single dose produced rapid, durable antidepressant effects. Phase 3 on track to initiate Q2 2026 (i.e., any day now) after a successful End-of-Phase 2 FDA meeting • Holds FDA Breakthrough Therapy Designation — exactly the kind of drug Trump’s EO targets • Added to the CRSP U.S. index and S&P Completion Index in March 2026, triggering mandatory passive fund buying from $3 trillion+ in indexed assets • Cash runway into early 2029 — no near-term dilution risk • Pipeline beyond BPL-003: VLS-01 (DMT buccal film, Phase 2 topline H2 2026), EMP-01 (R-MDMA for social anxiety, Phase 2a data expected soon) The sell-side: 14 analysts, 3 Strong Buy, 11 Buy, 0 Hold, 0 Sell. Average PT $13.33 (246% upside). Lowest PT is $7.00 — the most bearish analyst on the Street sees an 82% gain from here. GHRS — GH Research ($16.77) Lead asset is GH001, an inhaled mebufotenin for TRD. This is the one with the best Phase 2b data in the entire psychedelic space. The data: • Phase 2b primary endpoint met: -15.5 point placebo-adjusted MADRS reduction at Day 8 (p<0.0001). For context, esketamine (Spravato) showed roughly -4 points in its pivotal trials. GH001’s effect size is roughly 4x the approved standard of care • 57.5% remission at Day 8. 73% remission at 6 months with an average of only \~4 treatments • Median psychedelic experience lasts approximately 11 minutes. Psilocybin (Compass/CMPS) takes 4-6 hours. This is the healthcare economics moat — a clinic can treat 8-10 patients per chair per day instead of 2 • 97.4% of patients were discharge-ready within 1 hour • No serious adverse events in the double-blind trial • FDA lifted the clinical hold on GH001 in January 2026. Phase 3 initiation targeted for 2H 2026 • Phase 2b results published in JAMA Psychiatry — the gold-standard peer-reviewed psychiatric journal The sell-side: 9 analysts, 2 Strong Buy, 7 Buy, 0 Hold, 0 Sell. Average PT $39.25 (134% upside). Lowest PT is $25.00 — the bear case is still 49% upside. Why this EO changes the game 1. National priority vouchers = accelerated review timelines. Both BPL-003 and GH001 hold Breakthrough Therapy Designation. If either receives a national priority voucher next week, the path from Phase 3 to approval compresses from the normal 2-3 year timeline to potentially 12-18 months. That changes the NPV math materially. 2. Regulatory risk just evaporated. The single biggest overhang on psychedelic stocks has always been “will the FDA actually approve a Schedule I psychedelic?” That question is now being answered from the Oval Office. The FDA commissioner stood next to the President and said they’re fast-tracking these drugs. That’s about as clear a signal as you can get. 3. DEA scheduling risk diminishes. The DEA proposed increasing the 2026 manufacturing quota for 5-MeO-DMT to 30,000 grams. The administration is actively expanding supply, not restricting it. 4. Institutional capital comes off the sidelines. Many healthcare-focused funds couldn’t or wouldn’t touch psychedelic stocks because of regulatory uncertainty. This EO gives them political cover to deploy. ATAI’s CRSP index inclusion is already forcing passive ownership — now active managers have cover too. The catalyst calendar • Next week: FDA issues national priority vouchers for three psychedelics. Watch for BPL-003 or GH001 to be named • May 2026: ATAI Q1 earnings + potential EMP-01 Phase 2a readout • May/June 2026: BPL-003 Phase 3 first-patient-dosed announcement • H2 2026: GHRS Phase 3 initiation + ATAI VLS-01 Phase 2b topline data Positions: 63,000 shares ATAI @ $3.40 avg, 5000 shares GHRS @ $13.10 avg. Looking at Jan 2027 calls on ATAI TL;DR: Trump just told the FDA to fast-track psychedelics. Two companies with Breakthrough Therapy Designation and the best clinical data in the space are about to start Phase 3 trials. Sell-side is unanimously bullish with the bear case still showing 49-82% upside. The regulatory environment just permanently changed. Monday should be interesting.